{
  "abstract": null,
  "abstract_shown": false,
  "affiliations": [
    "1 Guangdong Lung Cancer Institute, Guangdong Provincial People`s Hospital, Guangzhou, Guangdong, China",
    "Center for Environment and Population Health, Griffith University, Nathan, Queensland, Australia",
    "Guangdong Provincial People’s Hospital, Guangzhou, Guangdong, China",
    "Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China",
    "Biocity Biopharmaceutics Co. Ltd, Shanghai, China"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 8,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Yi-Long Wu"
    },
    {
      "affs": [
        1
      ],
      "name": "Hai-jun Guo"
    },
    {
      "affs": [
        2
      ],
      "name": "Chongrui Xu"
    },
    {
      "affs": [
        3
      ],
      "name": "Fa-Man Xiao"
    },
    {
      "affs": [
        3
      ],
      "name": "Ji-Lin Guan"
    },
    {
      "affs": [
        3
      ],
      "name": "Yue-Li Sun"
    },
    {
      "affs": [
        4
      ],
      "name": "Xiang-Yun Ye"
    },
    {
      "affs": [
        4
      ],
      "name": "Yi-Wei Wang"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/c91z7je2ndh87.bib",
  "cited_by": 0,
  "doi": "10.1136/jitc-2026-sitc2026.0535",
  "fulltext_url": null,
  "id": "c91z7je2ndh87",
  "issns": [
    "2051-1426"
  ],
  "landing_url": "https://doi.org/10.1136/jitc-2026-sitc2026.0535",
  "language": "en",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "lcc",
      "RC254-282"
    ],
    [
      "openalex",
      "2730|Cancer Immunotherapy and Biomarkers"
    ]
  ],
  "openalex": "W7225329628",
  "pdf_url": "https://jitc.bmj.com/content/14/Suppl_2/A597.full.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-11-06",
  "publisher": "BMJ Publishing Group",
  "ris": "https://research.draconitic.com/paper/c91z7je2ndh87.ris",
  "sources": [
    {
      "first_seen": "2026-11-06T14:21:04Z",
      "native_id": "e2c63d8aa2c04f878111aded6c4a7260",
      "source": "doaj",
      "url": "https://doi.org/10.1136/jitc-2026-sitc2026.0535"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Cancer Immunotherapy and Biomarkers",
      "subfield": "oncology"
    }
  ],
  "title": "535 BC3195, a novel cadherin-3 targeting antibody drug conjugate, combined with pembrolizumab in patients with advanced solid malignancies: preliminary results from a phase I/II study (BC3195-103/G36)",
  "title_text": "535 BC3195, a novel cadherin-3 targeting antibody drug conjugate, combined with pembrolizumab in patients with advanced solid malignancies: preliminary results from a phase I/II study (BC3195-103/G36)",
  "type": "peer-reviewed",
  "updated_at": "2026-11-08T14:20:17Z",
  "url": "https://research.draconitic.com/paper/c91z7je2ndh87",
  "venue": "Journal for ImmunoTherapy of Cancer",
  "versions": []
}